{
  "DOI": "10.1186/s40246-024-00610-y",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-024-00610-y",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eBackground\u003c/jats:title\u003e\n                \u003cjats:p\u003eCYP2C8 is responsible for the metabolism of 5% of clinically prescribed drugs, including antimalarials, anti-cancer and anti-inflammatory drugs. Genetic variability is an important factor that influences CYP2C8 activity and modulates the pharmacokinetics, efficacy and safety of its substrates.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eResults\u003c/jats:title\u003e\n                \u003cjats:p\u003eWe profiled the genetic landscape of \u003cjats:italic\u003eCYP2C8\u003c/jats:italic\u003e variability using data from 96 original studies and data repositories that included a total of 33,185 unrelated participants across 44 countries and 43 ethnic groups. The reduced function allele \u003cjats:italic\u003eCYP2C8*2\u003c/jats:italic\u003e was most common in West and Central Africa with frequencies of 16–36.9%, whereas it was rare in Europe and Asia (\u0026lt; 2%). In contrast, \u003cjats:italic\u003eCYP2C8*3\u003c/jats:italic\u003e and \u003cjats:italic\u003eCYP2C8*4\u003c/jats:italic\u003e were common throughout Europe and the Americas (6.9–19.8% for \u003cjats:italic\u003e*3\u003c/jats:italic\u003e and 2.3–7.5% for \u003cjats:italic\u003e*4\u003c/jats:italic\u003e), but rare in African and East Asian populations. Importantly, we observe pronounced differences (\u0026gt; 2.3-fold) between neighboring countries and even between geographically overlapping populations. Overall, we found that 20–60% of individuals in Africa and Europe carry at least one \u003cjats:italic\u003eCYP2C8\u003c/jats:italic\u003e allele associated with reduced metabolism and increased adverse event risk of the anti-malarial amodiaquine. Furthermore, up to 60% of individuals of West African ancestry harbored variants that reduced the clearance of pioglitazone, repaglinide, paclitaxel and ibuprofen. In contrast, reduced function alleles are only found in \u0026lt; 2% of East Asian and 8.3–12.8% of South and West Asian individuals.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e\u003cjats:sec\u003e\n                \u003cjats:title\u003eConclusions\u003c/jats:title\u003e\n                \u003cjats:p\u003eCombined, the presented analyses mapped the genetic and inferred functional variability of \u003cjats:italic\u003eCYP2C8\u003c/jats:italic\u003e with high ethnogeographic resolution. These results can serve as a valuable resource for \u003cjats:italic\u003eCYP2C8\u003c/jats:italic\u003e allele frequencies and distribution estimates of CYP2C8 phenotypes that could help identify populations at risk upon treatment with CYP2C8 substrates. The high variability between ethnic groups incentivizes high-resolution pharmacogenetic profiling to guide precision medicine and maximize its socioeconomic benefits, particularly for understudied populations with distinct genetic profiles.\u003c/jats:p\u003e\n              \u003c/jats:sec\u003e",
  "alternative-id": [
    "610"
  ],
  "article-number": "40",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "1 April 2024"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "16 April 2024"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "22 April 2024"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "V.M.L. is co-founder, CEO and shareholder of HepaPredict AB. Y.Z. and V.M.L. are co-founders and shareholders of Shanghai Hepo Biotechnology Ltd. The other authors declare no competing interests."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Camara",
      "given": "Mahamadou D.",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Zhou",
      "given": "Yitian",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "De Sousa",
      "given": "Taís Nóbrega",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Gil",
      "given": "José P.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Djimde",
      "given": "Abdoulaye A.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Lauschke",
      "given": "Volker M.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2024,
        4,
        22
      ]
    ],
    "date-time": "2024-04-22T08:02:03Z",
    "timestamp": 1713772923000
  },
  "deposited": {
    "date-parts": [
      [
        2024,
        4,
        22
      ]
    ],
    "date-time": "2024-04-22T08:05:36Z",
    "timestamp": 1713773136000
  },
  "funder": [
    {
      "DOI": "10.13039/501100001322",
      "award": [
        "3000038516",
        "3000038516"
      ],
      "doi-asserted-by": "publisher",
      "name": "South African Medical Research Council"
    },
    {
      "DOI": "10.13039/501100002794",
      "award": [
        "23-0763PT"
      ],
      "doi-asserted-by": "publisher",
      "name": "Cancerfonden"
    },
    {
      "DOI": "10.13039/501100001713",
      "award": [
        "RIA2017T-2018",
        "RIA2017T-2018"
      ],
      "doi-asserted-by": "publisher",
      "name": "European and Developing Countries Clinical Trials Partnership"
    },
    {
      "DOI": "10.13039/501100004359",
      "award": [
        "2021-02801"
      ],
      "doi-asserted-by": "publisher",
      "name": "Vetenskapsrådet"
    },
    {
      "DOI": "10.13039/501100004047",
      "doi-asserted-by": "crossref",
      "name": "Karolinska Institute"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        24
      ]
    ],
    "date-time": "2024-04-24T17:26:29Z",
    "timestamp": 1713979589689
  },
  "is-referenced-by-count": 0,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2024,
        4,
        22
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-online": {
      "date-parts": [
        [
          2024,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            4,
            22
          ]
        ],
        "date-time": "2024-04-22T00:00:00Z",
        "timestamp": 1713744000000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2024,
            4,
            22
          ]
        ],
        "date-time": "2024-04-22T00:00:00Z",
        "timestamp": 1713744000000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-024-00610-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1186/s40246-024-00610-y/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1186/s40246-024-00610-y.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2024,
        4,
        22
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2024,
        4,
        22
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/j.clpt.2004.12.267",
      "author": "RA Totah",
      "doi-asserted-by": "publisher",
      "first-page": "341",
      "journal-title": "Clin Pharmacol Ther",
      "key": "610_CR1",
      "unstructured": "Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther. 2005;77:341–52.",
      "volume": "77",
      "year": "2005"
    },
    {
      "DOI": "10.1038/s41397-022-00288-2",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "284",
      "journal-title": "Pharmacogenomics J",
      "key": "610_CR2",
      "unstructured": "Zhou Y, Lauschke VM. The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data. Pharmacogenomics J. 2022;22:284–93.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.1111/j.1742-7843.2008.00351.x",
      "author": "H Gréen",
      "doi-asserted-by": "publisher",
      "first-page": "130",
      "journal-title": "Basic Clin Pharmacol Toxicol",
      "key": "610_CR3",
      "unstructured": "Gréen H, Söderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EÅ, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol. 2009;104:130–7.",
      "volume": "104",
      "year": "2009"
    },
    {
      "DOI": "10.1038/sj.clpt.6100122",
      "author": "S Parikh",
      "doi-asserted-by": "publisher",
      "first-page": "197",
      "journal-title": "Clin Pharmacol Ther",
      "key": "610_CR4",
      "unstructured": "Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82:197–203.",
      "volume": "82",
      "year": "2007"
    },
    {
      "DOI": "10.1186/s12936-021-03620-6",
      "author": "L Pernaute-Lau",
      "doi-asserted-by": "publisher",
      "first-page": "90",
      "journal-title": "Malar J",
      "key": "610_CR5",
      "unstructured": "Pernaute-Lau L, Morris U, Msellem M, Mårtensson A, Björkman A, Gil JP. Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated plasmodium falciparum malaria in Zanzibar. Malar J. 2021;20:90.",
      "volume": "20",
      "year": "2021"
    },
    {
      "DOI": "10.1097/00008571-200110000-00006",
      "author": "D Dai",
      "doi-asserted-by": "publisher",
      "first-page": "597",
      "journal-title": "Pharmacogenetics",
      "key": "610_CR6",
      "unstructured": "Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597–607.",
      "volume": "11",
      "year": "2001"
    },
    {
      "DOI": "10.3109/00498254.2010.487163",
      "author": "Y Gao",
      "doi-asserted-by": "publisher",
      "first-page": "467",
      "journal-title": "Xenobiotica",
      "key": "610_CR7",
      "unstructured": "Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions. Xenobiotica. 2010;40:467–75.",
      "volume": "40",
      "year": "2010"
    },
    {
      "DOI": "10.1002/bdd.1842",
      "author": "L Yu",
      "doi-asserted-by": "publisher",
      "first-page": "278",
      "journal-title": "Biopharm Drug Dispos",
      "key": "610_CR8",
      "unstructured": "Yu L, Shi D, Ma L, Zhou Q, Zeng S. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013;34:278–87.",
      "volume": "34",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.dmpk.2015.07.003",
      "author": "C Tsukada",
      "doi-asserted-by": "publisher",
      "first-page": "366",
      "journal-title": "Drug Metab Pharmacokinet",
      "key": "610_CR9",
      "unstructured": "Tsukada C, Saito T, Maekawa M, Mano N, Oda A, Hirasawa N, et al. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation. Drug Metab Pharmacokinet. 2015;30:366–73.",
      "volume": "30",
      "year": "2015"
    },
    {
      "DOI": "10.1007/BF03256440",
      "author": "E García-Martín",
      "doi-asserted-by": "publisher",
      "first-page": "29",
      "journal-title": "Mol Diagn Ther",
      "key": "610_CR10",
      "unstructured": "García-Martín E, Martínez C, Ladero JM, Agúndez JAG. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10:29–40.",
      "volume": "10",
      "year": "2006"
    },
    {
      "DOI": "10.1186/1475-2875-11-125",
      "author": "GM Paganotti",
      "doi-asserted-by": "publisher",
      "first-page": "125",
      "journal-title": "Malar J",
      "key": "610_CR11",
      "unstructured": "Paganotti GM, Gramolelli S, Tabacchi F, Russo G, Modiano D, Coluzzi M, et al. Distribution of human CYP2C8*2 allele in three different African populations. Malar J. 2012;11:125.",
      "volume": "11",
      "year": "2012"
    },
    {
      "DOI": "10.1002/cpt.690",
      "author": "Y Zhou",
      "doi-asserted-by": "publisher",
      "first-page": "688",
      "journal-title": "Clin Pharmacol Ther",
      "key": "610_CR12",
      "unstructured": "Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688–700.",
      "volume": "102",
      "year": "2017"
    },
    {
      "DOI": "10.1080/17425255.2022.2049235",
      "author": "L Pernaute-Lau",
      "doi-asserted-by": "publisher",
      "first-page": "39",
      "journal-title": "Expert Opin Drug Metab Toxicol",
      "key": "610_CR13",
      "unstructured": "Pernaute-Lau L, Camara M, de Sousa TN, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opin Drug Metab Toxicol. 2022;18:39–59.",
      "volume": "18",
      "year": "2022"
    },
    {
      "DOI": "10.1038/s41586-020-2308-7",
      "author": "KJ Karczewski",
      "doi-asserted-by": "publisher",
      "first-page": "434",
      "journal-title": "Nature",
      "key": "610_CR14",
      "unstructured": "Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.",
      "volume": "581",
      "year": "2020"
    },
    {
      "DOI": "10.1097/FPC.0b013e3283653b27",
      "author": "CL Aquilante",
      "doi-asserted-by": "publisher",
      "first-page": "721",
      "journal-title": "Pharmacogenet Genomics",
      "key": "610_CR15",
      "unstructured": "Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013;23:721–8.",
      "volume": "23",
      "year": "2013"
    },
    {
      "DOI": "10.2133/dmpk.17.374",
      "author": "A Soyama",
      "doi-asserted-by": "publisher",
      "first-page": "374",
      "journal-title": "Drug Metab Pharmacokinet",
      "key": "610_CR16",
      "unstructured": "Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet. 2002;17:374–7.",
      "volume": "17",
      "year": "2002"
    },
    {
      "DOI": "10.1124/dmd.105.003830",
      "author": "H Hichiya",
      "doi-asserted-by": "publisher",
      "first-page": "630",
      "journal-title": "Drug Metab Dispos",
      "key": "610_CR17",
      "unstructured": "Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005;33:630–6.",
      "volume": "33",
      "year": "2005"
    },
    {
      "DOI": "10.1097/FPC.0b013e32805b72c1",
      "author": "Y Saito",
      "doi-asserted-by": "publisher",
      "first-page": "461",
      "journal-title": "Pharmacogenet Genomics",
      "key": "610_CR18",
      "unstructured": "Saito Y, Katori N, Soyama A, Nakajima Y, Yoshitani T, Kim S-R, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics. 2007;17:461–71.",
      "volume": "17",
      "year": "2007"
    },
    {
      "DOI": "10.2133/dmpk.23.165",
      "author": "R Singh",
      "doi-asserted-by": "publisher",
      "first-page": "165",
      "journal-title": "Drug Metab Pharmacokinet",
      "key": "610_CR19",
      "unstructured": "Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE. Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet. 2008;23:165–74.",
      "volume": "23",
      "year": "2008"
    },
    {
      "DOI": "10.1111/j.1742-7843.2010.00669.x",
      "author": "N Hanioka",
      "doi-asserted-by": "publisher",
      "first-page": "359",
      "journal-title": "Basic Clin Pharmacol Toxicol",
      "key": "610_CR20",
      "unstructured": "Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. Basic Clin Pharmacol Toxicol. 2011;108:359–62.",
      "volume": "108",
      "year": "2011"
    },
    {
      "DOI": "10.2217/pgs.15.46",
      "author": "M-Y Lee",
      "doi-asserted-by": "publisher",
      "first-page": "929",
      "journal-title": "Pharmacogenomics",
      "key": "610_CR21",
      "unstructured": "Lee M-Y, Apellniz-Ruiz M, Johansson I, Vikingsson S, Bergmann TK, Brøsen K, et al. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics. 2015;16:929–37.",
      "volume": "16",
      "year": "2015"
    },
    {
      "DOI": "10.1111/j.1365-2125.2012.04343.x",
      "author": "CL Aquilante",
      "doi-asserted-by": "publisher",
      "first-page": "217",
      "journal-title": "Br J Clin Pharmacol",
      "key": "610_CR22",
      "unstructured": "Aquilante CL, Kosmiski LA, Bourne DWA, Bushman LR, Daily EB, Hammond KP, et al. Impact of the CYP2C8 *3 polymorphism on the drug–drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013;75:217–26.",
      "volume": "75",
      "year": "2013"
    },
    {
      "DOI": "10.1124/dmd.110.036921",
      "author": "D Tomalik-Scharte",
      "doi-asserted-by": "publisher",
      "first-page": "927",
      "journal-title": "Drug Metab Dispos",
      "key": "610_CR23",
      "unstructured": "Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos. 2011;39:927–32.",
      "volume": "39",
      "year": "2011"
    },
    {
      "DOI": "10.1007/s00726-010-0743-8",
      "author": "H Jiang",
      "doi-asserted-by": "publisher",
      "first-page": "1195",
      "journal-title": "Amino Acids.",
      "key": "610_CR24",
      "unstructured": "Jiang H, Zhong F, Sun L, Feng W, Huang Z-X, Tan X. Structural and functional insights into CYP2C83: a genetic polymorph of cytochrome P450 2C8. Amino Acids. 2011;40:1195–204.",
      "volume": "40",
      "year": "2011"
    },
    {
      "DOI": "10.3390/ijms20184626",
      "author": "WR Arnold",
      "doi-asserted-by": "publisher",
      "first-page": "4626",
      "journal-title": "Int J Mol Sci",
      "key": "610_CR25",
      "unstructured": "Arnold WR, Zelasko S, Meling DD, Sam K, Das A. Polymorphisms of CYP2C8 alter first-electron transfer kinetics and increase catalytic uncoupling. Int J Mol Sci. 2019;20:4626.",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.2217/pgs.09.82",
      "author": "EB Daily",
      "doi-asserted-by": "publisher",
      "first-page": "1489",
      "journal-title": "Pharmacogenomics",
      "key": "610_CR26",
      "unstructured": "Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10:1489–510.",
      "volume": "10",
      "year": "2009"
    },
    {
      "DOI": "10.1186/s12864-019-6296-7",
      "author": "M Vicente",
      "doi-asserted-by": "publisher",
      "first-page": "915",
      "journal-title": "BMC Genom",
      "key": "610_CR27",
      "unstructured": "Vicente M, Priehodova E, Diallo I, Podgorna E, Poloni ES, Cerny V, Schlebusch CM. Population history and genetic adaptation of the Fulani nomads: inferences from genome-wide data and the lactase persistence trait. BMC Genom. 2019;20:915.",
      "volume": "20",
      "year": "2019"
    },
    {
      "DOI": "10.1073/pnas.93.23.13206",
      "author": "D Modiano",
      "doi-asserted-by": "publisher",
      "first-page": "13206",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "610_CR28",
      "unstructured": "Modiano D, Petrarca V, Sirima SB, Nebie I, Diallo D, Esposito F, Coluzzi M. Different response to Plasmodium falciparum malaria in West African sympatric ethnic groups. Proc Natl Acad Sci USA. 1996;93:13206–11.",
      "volume": "93",
      "year": "1996"
    },
    {
      "DOI": "10.1186/1475-2875-12-163",
      "author": "AB Tiono",
      "doi-asserted-by": "publisher",
      "first-page": "163",
      "journal-title": "Malar J",
      "key": "610_CR29",
      "unstructured": "Tiono AB, Sirima SB, Hamed K. Fulani show decreased susceptibility to Plasmodium falciparum infection versus Mossi: data from a community-wide screening and treatment of asymptomatic carriers in Burkina Faso. Malar J. 2013;12:163.",
      "volume": "12",
      "year": "2013"
    },
    {
      "DOI": "10.1371/journal.pone.0075675",
      "author": "B Maiga",
      "doi-asserted-by": "publisher",
      "journal-title": "PLoS ONE",
      "key": "610_CR30",
      "unstructured": "Maiga B, Dolo A, Toure O, Dara V, Tapily A, Campino S, et al. Human candidate polymorphisms in sympatric ethnic groups differing in malaria susceptibility in Mali. PLoS ONE. 2013;8: e75675.",
      "volume": "8",
      "year": "2013"
    },
    {
      "DOI": "10.1038/s41397-022-00284-6",
      "author": "S Haeggström",
      "doi-asserted-by": "publisher",
      "first-page": "247",
      "journal-title": "Pharmacogenomics J",
      "key": "610_CR31",
      "unstructured": "Haeggström S, Ingelman-Sundberg M, Pääbo S, Zeberg H. The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals. Pharmacogenomics J. 2022;22:247–9.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.1186/1475-2875-11-97",
      "author": "AR Anvikar",
      "doi-asserted-by": "publisher",
      "first-page": "97",
      "journal-title": "Malar J",
      "key": "610_CR32",
      "unstructured": "Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J. 2012;11:97.",
      "volume": "11",
      "year": "2012"
    },
    {
      "DOI": "10.1016/S1473-3099(21)00692-7",
      "author": "TJ Peto",
      "doi-asserted-by": "publisher",
      "first-page": "867",
      "journal-title": "Lancet Infect Dis",
      "key": "610_CR33",
      "unstructured": "Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022;22:867–78.",
      "volume": "22",
      "year": "2022"
    },
    {
      "DOI": "10.3109/00498259509061845",
      "author": "H Jewell",
      "doi-asserted-by": "publisher",
      "first-page": "199",
      "journal-title": "Xenobiotica",
      "key": "610_CR34",
      "unstructured": "Jewell H, Maggs JL, Harrison AC, O’Neill PM, Ruscoe JE, Park BK. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica. 1995;25:199–217.",
      "volume": "25",
      "year": "1995"
    },
    {
      "DOI": "10.2217/14622416.9.10.1385",
      "author": "JP Gil",
      "doi-asserted-by": "publisher",
      "first-page": "1385",
      "journal-title": "Pharmacogenomics",
      "key": "610_CR35",
      "unstructured": "Gil JP. Amodiaquine pharmacogenetics. Pharmacogenomics. 2008;9:1385–90.",
      "volume": "9",
      "year": "2008"
    },
    {
      "DOI": "10.1186/1475-2875-11-260",
      "author": "J Zwang",
      "doi-asserted-by": "publisher",
      "first-page": "260",
      "journal-title": "Malar J",
      "key": "610_CR36",
      "unstructured": "Zwang J, Dorsey G, Djimdé A, Karema C, Mårtensson A, Ndiaye J-L, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J. 2012;11:260.",
      "volume": "11",
      "year": "2012"
    }
  ],
  "reference-count": 36,
  "references-count": 36,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-024-00610-y"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "18"
}